Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Fineline Cube May 22, 2026
Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026
Company Deals

Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology

Fineline Cube Mar 20, 2023

Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...

Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Company Drug

AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China

Fineline Cube Mar 17, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...

Company Deals

Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development

Fineline Cube Mar 17, 2023

Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...

Company Drug

NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216

Fineline Cube Mar 17, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...

Company Drug

Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China

Fineline Cube Mar 17, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Mar 17, 2023

China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...

Company Deals

Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab

Fineline Cube Mar 17, 2023

US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology...

Policy / Regulatory

Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables

Fineline Cube Mar 17, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP)...

Company Drug

Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Mar 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...

Company Drug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

Fineline Cube Mar 17, 2023

China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...

Company Deals

Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms

Fineline Cube Mar 17, 2023

China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...

Company Drug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

Fineline Cube Mar 16, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Deals

ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705

Fineline Cube Mar 16, 2023

Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...

Company Medical Device

Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications

Fineline Cube Mar 16, 2023

Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...

Posts pagination

1 … 553 554 555 … 670

Recent updates

  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
  • Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU
  • Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC
  • Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Company Drug

Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.